Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Omnes Capital

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 239
Average round size
info
The average size of a deal this fund participated in
$13M
Portfolio companies 195
Rounds per year 10.39
Lead investments 39
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.18
Exits 85
Key employees 19
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity
Seed

Areas of investment

  • Biotechnology
  • Software
  • Health Care
  • Manufacturing
  • Medical Device
Summary

Omnes Capital is the famous VC, which was founded in 1999. The venture was found in Europe in France. The leading representative office of defined VC is situated in the Paris.

Besides them, we counted 19 critical employees of this fund in our database.

The standard case for the fund is to invest in rounds with 2-3 partakers. Despite the Omnes Capital, startups are often financed by Bpifrance, Ventech, Societe Generale Asset Management. The meaningful sponsors for the fund in investment in the same round are Bpifrance, Andera Partners, Seventure Partners. In the next rounds fund is usually obtained by Andera Partners, Ventech, Seventure Partners.

The top activity for fund was in 2009. Despite it in 2019 the fund had an activity. Comparing to the other companies, this Omnes Capital performs on 12 percentage points more the average number of lead investments. Speaking about the real fund results, this VC is 1 percentage points less often commits exit comparing to other organizations. The increased amount of exits for fund were in 2015. The fund is constantly included in 7-12 deals per year. The usual things for fund are deals in the range of 10 - 50 millions dollars.

We can highlight the next thriving fund investment areas, such as Medical Device, Internet. Among the most popular portfolio startups of the fund, we may highlight PayPal, Scality, BioVex. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - France. The fund has no exact preference in some founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Omnes Capital:
Typical Co-investors
Omnes Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Omnes Capital:

Funds with similar focus

Funds from France
Funds with similar focus located in France:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Dust Mobile

Telecommunications
$14M23 Nov 2022 City of Brussels, Belgium

Qantev

Analytics
Artificial Intelligence
Enterprise Software
Health Insurance
Insurance
InsurTech
Machine Learning
$11M25 Oct 2022 Paris, Ile-de-France, France

Capsule Corp. Labs

Blockchain
Cryptocurrency
Information Technology
Software
$5M12 Oct 2022 -

GOURMEY

Food and Beverage
Life Science
$56M05 Oct 2022 Paris, Ile-de-France, France

Ternoa

$7M15 Sep 2022 Biarritz, Aquitaine, France

WhiteLab Genomics

Biotechnology
Genetics
$10M12 Sep 2022 Paris, Ile-de-France, France

Qubit Pharmaceuticals

Biotechnology
$18M10 Jun 2022 -

Therapixel

Artificial Intelligence
Health Diagnostics
Medical Device
Software
$17M12 May 2022 Nice, Provence-Alpes-Côte d'Azur, France

Domain Therapeutics

Biotechnology
Health Care
Pharmaceutical
Therapeutics
$46M10 May 2022 France, Grand Est, France
News
Coave Therapeutics Closes €33M in Series B Financing

– Coave Therapeutics, a Paris, France-based clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases, raised a €21.2m ($25.1m) expansion of its Series B funding round, bringing the total raised to €33.1m ($39m).
– This round was led by Seroba Life Sciences, supported by new investors Théa Open Innovation and eureKARE alongside existing shareholders Fund+, Omnes Capital, V-Bio Ventures, Kurma Partners, Idinvest, GO Capital, and Sham Innovation Santé/Turenne.
– The company will use the proceeds to support the execution of its corporate strategy, which is focused on advancing its lead clinical program CTx-PDE6b for the treatment of PDE6b inherited retinal dystrophies, currently in Phase I/II clinical trial, towards pivotal trials, developing its AAV Ligand Conjugate (‘ALIGATER’) platform, which is designed to enhance the delivery and efficiency of AAV vectors via a proprietary chemical conjugation technology to produce targeted gene therapy products, advancing new preclinical programs, based on AAV-Ligand Conjugate capsids (coAAV), in rare CNS and Ocular diseases, including CTx-GBA1 for Parkinson’s disease and Gaucher Disease and CTx-ABCA4 for Stargardt’s disease, entering partnerships in key disease areas to progress novel coAAV candidates towards the clinic and to address other disease areas given the potential of the platform and the scope for targeting other tissues.

Elistair, The Pioneer in Tethered UAVs, Announces a €5M Series B Round to Accelerate Its International Expansion

– Elistair, a market leader in tethered drones, has raised €5M from Omnes and Starquest Capital, its historic investor.
– This Series B round follows an initial €2M funding round in 2018.
– Elistair counts national security and defense organizations amongst its customers, offering them two patented product ranges: an automated tethered drone: Orion 2 and tether stations capable of transforming free-flying drones into tethered drones.
– The Orion 2 drone acts as an aerial reconnaissance mast, substantially increasing the field of vision of operating forces and reducing vulnerable entry points.
– They are also used to deploy tactical communication networks, greatly increasing the range and coverage of military radios.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Omnes Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: